General Proximity inks Daiichi Sankyo deal to push precision small molecules into oncology

General Proximity, a San Francisco-based biotechnology company developing proximity-induced medicines, has signed a strategic multi-target collaboration with Daiichi Sankyo Co., Ltd. to co-develop cancer treatments using its proprietary OmniTAC discovery platform. The partnership, routed through the Daiichi Sankyo Research Institute in Boston, will focus on identifying first-in-class therapeutic candidates capable of modulating proteins traditionally viewed as “undruggable” in oncology.

The deal represents a major validation for General Proximity’s drug discovery model and underscores growing pharmaceutical appetite for proximity-based small molecule therapeutics that offer an alternative to more established modalities such as antibodies and inhibitors. Under the terms of the agreement, General Proximity will apply its platform to screen and characterize novel effector–target protein pairs, while Daiichi Sankyo will integrate the findings into its internal oncology development pipeline.

The collaboration is non-exclusive and financial terms have not been disclosed. However, analysts believe the partnership places General Proximity firmly on the radar of institutional investors and pharma strategists seeking next-generation approaches in precision oncology.

How is General Proximity’s OmniTAC platform changing the drug discovery approach for undruggable targets?

The OmniTAC platform operates on the principle of induced proximity, a mechanism wherein small molecules are used to bring two proteins into close spatial alignment. This forced interaction leads to a desired biological response, such as degradation or modulation of protein activity. Such an approach bypasses the limitations of traditional inhibition-based drugs and opens therapeutic access to proteins that have long resisted conventional drug development techniques.

By enabling control over proximity rather than activity, General Proximity’s technology offers a fundamental shift in how small molecules interact with biological systems. According to the company’s founder and Chief Executive Officer Armand B. Cognetta III, this capability makes it possible to control biology with greater precision, ultimately improving efficacy while reducing off-target toxicity. The OmniTAC platform allows unbiased screening of effector proteins and disease targets, giving it broad applicability across therapeutic areas.

Why is Daiichi Sankyo betting on proximity-based therapeutics for the next wave of cancer treatments?

General Proximity’s partnership with Daiichi Sankyo is part of a broader strategy to scale the reach of its technology beyond internal assets. The company continues to advance in-house preclinical programs focused on cardiometabolic disease, neurodegeneration, and longevity, in addition to oncology. Executives have indicated that the modularity of the OmniTAC platform allows for rapid extension into new indications, particularly where current drug modalities have failed.

The announcement comes at a time of accelerated growth for the American biotech firm, which formally launched in January 2025 after securing a total of 16 million dollars in capital. The funding included an 8 million dollar seed round led by Felicis Ventures, with early backing from Y Combinator and Rock Creek Capital’s Jim Dahl. Additional support came from venture firms such as Modi Ventures and age1, as well as grants from institutions including the Advanced Research Projects Agency for Health and the National Cancer Institute.

Investor confidence in the platform is further reflected in the profile of General Proximity’s angel backers, which include some of the most prominent names in technology and biotech. Among them are Jeff Dean, Head of Google AI, Ben Mann, co-author of GPT-3 and co-founder of Anthropic, and Trevor Martin, Chief Executive Officer of Mammoth Biosciences. The syndicate also features Juan Benet, founder of Filecoin, Uri Lopatin of Pardes Biosciences, and Nish Bhat, co-founder of Color Health.

What gives General Proximity’s leadership team an edge in building a high-impact biotech platform?

The scientific pedigree of the company is equally strong. The founding team includes researchers trained at the Scripps Research Institute, Broad Institute of Harvard and MIT, Yale University, Oxford, Cambridge, the University of Pennsylvania, Johns Hopkins University, Columbia University, and the University of California San Francisco. Several team members are alumni of pharmaceutical majors such as Genentech, Merck, Novartis, GlaxoSmithKline, and Alnylam Pharmaceuticals. Many also trained under pioneers of proximity-based therapeutics, including Craig Crews and Amit Choudhary.

General Proximity’s Scientific and Strategic Advisory Board includes veteran biopharma leaders such as Martin Babler, formerly of Genentech and Principia Biopharma, Lawrence Hamann, who held senior roles at Bristol-Myers Squibb, Novartis, and Celgene, and Andy Crew, who previously worked with Astellas and Arvinas. The board also includes academic experts in cancer biology, neurodegeneration, and small molecule design.

The startup has already attracted significant attention from pharmaceutical firms and has secured five Golden Ticket awards from innovation programs run by AbbVie, Astellas, Servier, Ono Pharmaceutical, and Bristol-Myers Squibb. It was also selected to join Johnson & Johnson’s JLabs incubator program, further solidifying its visibility in the global biotech ecosystem.

How does OmniTAC compare to PROTACs and molecular glues in tackling complex protein biology?

Within the broader drug development landscape, proximity-based therapeutics are beginning to carve out a space parallel to proteolysis targeting chimeras (PROTACs) and molecular glue degraders. While PROTACs primarily aim at protein degradation through E3 ligase recruitment, platforms like OmniTAC offer more flexible applications, including activation or inhibition, depending on the target biology. This flexibility positions General Proximity to work across multiple disease modalities rather than being constrained to degradation alone.

Industry experts see the Daiichi Sankyo alliance as a pivotal move for both parties. For the Japanese pharmaceutical company, the collaboration aligns with its broader push to diversify its oncology pipeline beyond antibody-drug conjugates, an area where it has been a dominant player through assets like Enhertu. For General Proximity, the deal may serve as a blueprint for future partnerships in non-oncology disease areas such as metabolic and neurological conditions, both of which are included in its internal development pipeline.

What commercial and scientific opportunities does General Proximity’s pipeline offer investors?

The market opportunity is substantial. General Proximity estimates that the total addressable market for its therapeutic areas exceeds 250 billion dollars annually. By tapping into targets that have historically eluded traditional drug development, the biotech firm aims to dramatically expand the universe of treatable diseases.

Analysts covering early-stage biotech partnerships believe the company’s next major milestone will be its first Investigational New Drug (IND) filing, expected sometime in the next 12 to 18 months. Success on this front would further elevate its standing among venture-backed biotechs and increase the likelihood of downstream licensing deals, co-development arrangements, or even acquisition interest.

The partnership with Daiichi Sankyo may also spur similar activity across the pharmaceutical sector. As proximity-based modalities mature, more firms are expected to seek external innovation through platform collaborations. General Proximity’s early traction suggests it is well-positioned to capitalize on this trend and emerge as a key player in shaping the future of small molecule drug discovery.

The coming year will likely be pivotal. With multiple preclinical programs in motion and growing industry validation, General Proximity is entering a new phase of development where scientific ambition must meet clinical translation. The collaboration with Daiichi Sankyo marks a decisive step in that journey, offering both technical synergy and a potential pathway to market for therapies built on induced proximity.

What are the key takeaways from General Proximity’s partnership with Daiichi Sankyo?

• General Proximity has signed a multi-target oncology collaboration with Daiichi Sankyo Co., Ltd., focused on discovering first-in-class cancer therapeutics using the OmniTAC™ platform.
• The platform enables proximity-induced modulation of proteins that have traditionally been considered undruggable in oncology and other diseases.
• Daiichi Sankyo will leverage OmniTAC to identify effector–target protein pairs for integration into its internal development pipeline.
• The partnership follows General Proximity’s public launch in January 2025 and a $16 million capital raise led by Felicis Ventures, with backing from Y Combinator and prominent angel investors.
• General Proximity’s scientific team includes researchers from Scripps, Broad, Yale, Oxford, Genentech, Novartis, Merck, and other leading institutions.
• The company has received five Golden Ticket awards from major pharma players and was selected for Johnson & Johnson’s JLabs incubator.
• General Proximity’s pipeline extends beyond oncology into cardiometabolic disease, neurodegeneration, and longevity, targeting a $250 billion addressable market.
• The OmniTAC platform offers a differentiated mechanism compared to PROTACs or molecular glues, allowing for activation, inhibition, or degradation of target proteins.
• The first Investigational New Drug (IND) filings are expected in the next 12 to 18 months, with analysts watching for further pharma collaborations.
• The deal positions General Proximity as an emerging platform biotech at the forefront of induced proximity therapeutics, with broader implications for the future of small molecule drug discovery.